

*01 P 14511*

DEC 27 2007

PATENT & TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

more Patent Application of ) **MAIL STOP AF**  
Nancy M. Lee et al. )  
Application No.: 10/690,880 ) Group Art Unit: 1636  
Filed: October 22, 2003 ) Examiner: WALTER SCHLAPKOHL  
For: BIOMARKER PANEL FOR ) Confirmation No.: 8369  
COLORECTAL CANCER )

**DECLARATION UNDER 37 C.F.R. § 1.132**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I, Nancy M. Lee, Ph.D., hereby declare:

1. That I am a citizen of the United States of America, residing at 1830 Funston Avenue, San Francisco, California 94116.
2. That I have a Ph.D. in the field of biochemistry.
3. That my curriculum vitae is attached hereto as Exhibit A.
4. That I am a co-inventor of the application identified above.
5. That I have read and I am familiar with the above-identified application, including the Office Action dated July 25, 2007.
6. I understand that that Examiner is alleging that the pending claims lack written description for the terms:

- (a) "independently validated control" or "validated control (of any kind)" (see, e.g., the Final Office Action at page 6); and
- (b) "...an increase in at least one cDNA in the sample compared to cDNA levels from the independently validated normal control identifies the subject as a

candidate for the management of colorectal cancer and polyps..." (claim 57; Final Office Action at page 6).

However, it is also my understanding that the Examiner states in the Office Action mailed September 11, 2006, that the specification supports the use of "verified" normal counterparts (see, e.g., the Office Action of September 11, 2006).

The controls used in the invention are "validated" or "verified" as normal based upon a number of factors, all of which are routine in the art, including symptoms of various gastrointestinal diseases and disorder (e.g., colorectal bleeding, tissue morphology) as well as familial history and self history (FHS) (see, e.g., American Journal of Epidemiology Vol. 141, No. 9: 863-871, 1995; attached hereto as Exhibit B). For example, paragraph [0026] of the specification provides support for the risk associated with subjects having a familial or self history of colorectal cancer as being 3-4x higher in the population. Accordingly, one of skill in the art would recognize that you would not want to include, as controls, those that have an increase risk or predisposition to the disease you are trying to detect. "Verified" and "validated" are synonymous when used in conjunction to the term "control". A "verified control," as the Examiner indicates, is supported by the application and refers to a subject that prospectively or retrospectively can be included as a normal control subject because the subject does not have or does not develop a cancer or polyp and lacks FHS of such diseases. The term "validated control" also refers to a subject that prospectively or retrospectively can be included as a normal control subject and does not have or does not develop a cancer or polyp and lacks FHS of such diseases. Samples taken from such subjects are indicative of a control population or "normals".

A person of ordinary skill in the art, based upon the disclosure and the information available in the art would recognize a "verified control" or "normal" for the purposes of the invention. Furthermore, although the term "validated control" is used in the specification (see, e.g., paragraph [0027]), the term is synonymous with "verified control," a term that the Examiner has indicated as supported by the specification.

The Examiner also alleges that the specification lacks written description for identifying a subject with an increase in expression of a biomarker as a candidate for colorectal cancer/polyp management. The Examiner is directed to the claims as-filed, which indicate that a change in a biomarker identifies a subject as a candidate for management (see, e.g., claims 49 and 56-58). Furthermore, the data as originally filed (see Figures 3A and 3C) show that an increase in IL-8 and COX2 are associated with colorectal cancer. Thus, an increase in the biomarkers of SEQ ID NO:1 and 2 (as recited in claim 49 as originally filed) indicate a subject for colorectal cancer management. As yet further evidence, Table 1 (below) indicates that IL-8, COX2 and SAA1 are increased relative to controls in human subjects thereby providing additional evidence (data supported and contemplated in the specification as-filed) that such subjects are at risk of having or having colorectal cancer. This includes an increase in SAA1 expression as claimed in the application at the time of filing.

6. I also understand the Examiner alleges that the claims are not enabled by the specification. For example, at page 10-11 of the Office Action mailed July 25, 2007, the Examiner alleges that because:

"...the state of the art was underdeveloped both with respect to the use of nucleic acids to diagnose and manage disorder in general, as well as with respect to the use of nucleic acids for the management of patient care and discovery of therapeutic interventions for CRC and colorectal polyps in particular."

and

...while Applicant points to support in the specification to show that differences in gene expression were observed for panels of biomarkers in the context of normal and disease tissue in both a mouse MIN model of colorectal polyps and in human specimens, the biomarker panels are not comprised of the same biomarkers recited in the claims." Specifically, Applicants' claim 49 is drawn to the use of any two from the group. . .IL-8, PTGS-2 (COX2) and SAA1..."

Regarding the Examiner's first statement, the invention is an advancement of the technology that was previously available for the management of patient care. The invention identifies a number of markers indicative of colorectal cancer and polyps.

Regarding the Examiner's statements at page 10 that the data does not support the use of any 2 of the markers selected from the group consisting of IL-8, COX2 and SAA1 in methods or compositions for determining colorectal cancer or colorectal polyps in a subject (e.g., as set forth in claim 79), I contemplated based upon data available that the markers used and now claimed are indicative of colorectal cancer and polyps.

The development of colorectal cancer progresses through a series of stages. Initial morphology of the colon often appears normal, however, the data provided by the present application demonstrates that even in normal appearing mucosa of the colon, biological changes are taking place or have taken place. As these molecular changes occur, polyps are often produced, followed by cancerous lesions. Thus, it is important to identify these molecular changes in normal mucosa and polyps to identify the risk and development of cancerous lesions and provide patient care and management. In conception and reduction to practice of the disclosed invention, including the pending claims, a number of markers were identified that are useful for measuring the morphologically unseen, yet important changes, of the mucosa. Those markers included the polynucleotide and polypeptides listed in table of Figure 1 (these markers included IL-8, COX2 and SAA1). The original claimed invention includes a panel of these markers, as well as others. It is my understanding that the claimed invention was restricted to certain markers by the Patent Office for purposes of searching.

In further support of the invention as originally claimed and disclosed, as well as currently claimed, I provide the following additional data. This data corroborates and supports the original specification and data and the claimed invention.

The following data was obtained by rectal swab of subjects during colonoscopy. Swabs were obtained from normal appearing mucosa about 5-10 cm before the rectum of the subject. The swabs were stored in either PBS alone or in a media comprising RNase inhibitors. RNA was isolated from the samples and RT-PCR'ed using the primers identified in the specification.

Validated controls were identified by determining the subject's family history and self history of cancer and the subject's own upper GI diseases and disorders. In addition, morphological identification of polyps and cancerous lesions identified during colonoscopy were also used to categorize subjects.

Multiple samples were obtained from each subject as described in paragraph 30 of the specification. In particular, 4 samples were obtained from each subject in the control, FHSH and polyp group. The value of "N", in Table 1, refers to the number of samples measured (e.g., 23 subjects x 4 samples per subject = 92). Each sample was measured for a number of markers, including those specifically identified in the application, as filed, using the primers and probes specifically identified in the application, as filed.

For example, for a single control subject, four samples were obtained by colorectal swab. RNA was isolated and RT-PCR was performed using primers, as described in the specification (i.e., SEQ ID Nos: 45-88), to amplify the biomarkers (SEQ ID NOs:1-22) identified in the application. The process of RT-PCR is described in the specification at paragraphs 31-38. Each reaction also contained a control marker ( $\beta$ -actin).

For quantitation of marker expression, the fluorescence of the SYBR Green dye (see, e.g., paragraph 34) bound to the PCR products was measured after each cycle, and the cycle numbers were recorded when the accumulated signals crossed an arbitrary threshold (CT value). To normalize this value, a  $\Delta CT$  value was determined as the differences between the CT value for each marker and the CT value for  $\beta$ -actin or histidyl tRNA synthetase, which were repeated in each experiment as references and were shown not to vary significantly. For each marker a  $\Delta\Delta CT$  value was determined as the difference between the  $\Delta CT$  value for each individual sample and the average  $\Delta CT$  for a gene obtained from the control samples. These  $\Delta\Delta CT$  values were then used to calculate relative gene expression values as described in Applied Biosystems; User Bulletin 2; December 11, 1997). Thus, the "control" value is a  $\Delta\Delta CT$ , a decrease in RNA between the control and a particular condition for a particular marker results in an increase of the  $\Delta\Delta CT$  value

(indicative of reduced expression). Similarly, an increase in RNA between the control and a particular condition for a particular marker results in a decrease of the  $\Delta\Delta CT$  value. Accordingly, a decrease in a  $\Delta\Delta CT$  value is indicative of an increase in marker expression and an increase in  $\Delta\Delta CT$  value is indicative of a decrease in marker expression. Looking at Table 1, for example, IL-8 in the control group has a  $\Delta\Delta CT$  of 0.0050 and the cancer (PBS) group has a  $\Delta\Delta CT$  of -3.191, an increase in IL-8 expression in the cancer group compared to control.

Table 1:

	N=	p21	PPAR-a	COX2	IL-8	CXCR2	OPN	cOX1	Gro-a	Gro-g	PPAR-g	c-myc	CD44	mCSF-1	cyclin D	PPAR-d	SAA-1
Normal	92	0.0032	0.0002	-0.0016	0.0050	-0.0022	0.0040	0.0010	-0.0003	0.0042	0.0030	0.0009	0.0015	-0.0018	0.0000	-0.0041	0.0017
FHSH	148	0.0084	0.0352	-0.1701	-0.0139	0.0400	-0.3753	-0.2055	-0.2925	-0.3513	0.0959	-0.6824	0.4690	-0.4394	-0.3291	0.0662	-0.7372
polyps	100	0.1194	0.4066	-1.0155	-0.7683	-0.1969	-0.5657	0.0723	-0.5364	-0.3488	0.3836	-0.5599	-0.4329	-0.5711	-0.0130	0.0850	-1.0363
CA <sub>y</sub> , PBS	49	1.15	0.936	-2.2793	-3.191	-4.761	-1.368	0.8802	-1.527	-2.181	1.371	-1.604	-1.196	-0.614	0.3896	0.4484	-2.223
CA <sub>y</sub> , RNAP	62	0.761	0.21	-1.9632	-2.7	-0.12	-0.04	2.0847	-0.384	-1.104	0.188	-0.056	-0.082	0.434	0.0461	0.0944	-0.712

Normal = Subjects with no Family History or Self History of cancer (FHSH), no polyps, no colorectal cancer lesions, and no known upper GI diseases during colonoscopy.

FHSH = Subjects with a Family History or Self History of cancer (e.g., colorectal cancer), no polyps, no colorectal bleeding at the time of colonoscopy.

Polyps = Subjects with polyps with or without family or self history.

CA = Subjects with colorectal cancer.

CA(PBS) - Samples prepared in PBS.

CA(RNAP) - Samples prepared in RNA protection buffer.

White columns - Biphasic markers (e.g., an increase then a decrease during disease progression).

Dark grey - Markers with an increase in expression in polyps and colorectal cancer relative to normal controls.

Light grey - Markers with a decrease in expression in polyps and colorectal cancer relative to normal controls.

The data in Table 1, demonstrates that the markers identified in the specification (including those currently claimed as well as those subject to restriction requirement) can be used to identify subjects having colorectal cancer and polyps. In particular, IL-8 in the control population has  $\Delta\Delta CT$  value of 0.0050 and in the cancer population (PBS) has a  $\Delta\Delta CT$  value of -3.191; COX2 in the control population has a  $\Delta\Delta CT$  value of -0.0016 and in a cancer population (PBS) has a  $\Delta\Delta CT$  value of -2.2796; and SAA1 in the control population has a  $\Delta\Delta CT$  value of 0.0017 and in the cancer population (PBS) has a  $\Delta\Delta CT$  value of -2.223. These changes in value indicate a significant change in expression of the makers measured by RT-PCR.

As demonstrated by the data above, measuring at least two markers selected from IL-8, COX2 and SAA1 provides information regarding the subject's disposition and development of polyps or cancer. For example, (1) where an increase in IL-8 and COX2 is present in the subject compared to a control, the subject has or is at risk of having colorectal cancer or polyps; (2) where an increase in IL-8 and SAA1 is present in the subject compared to a control, the subject has or is at risk of having colorectal cancer or polyps; (3) where an increase in COX-2 and SAA1 is present in the subject compared to a control, the subject has or is at risk of having colorectal cancer or polyps; (4) where an increase in IL-8, COX2 and SAA1 is present in the subject compared to control the subject has or is at risk of having colorectal cancer or polyps; and (5) where an increase and then a decrease in SAA1 is observed and an increase of IL-8 and/or COX2 is observed the subject had polyps and has transitioned to colorectal cancer. As indicated above, SAA1 is a biphasic marker meaning that it changes during disease progression; however, SAA1 is elevated compared to control both at the polyp and cancer stages.

Accordingly, the data demonstrate that the measurement of any two biomarkers selected from IL-8, COX2 and SAA1 provide evidence of colorectal cancer or polyps in a subject when compared to controls (as originally indicated, contemplated and claimed by the present application and currently claimed).

7. I further declare that all statements made on my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false

Attorney's Docket No. 1034518-000006  
Application No. 10/690,880  
Page 9

statements and the like so made are punishable by fine or imprisonment, or both,  
under Section 1001 of Title 18 of the United States Code and that such willful false  
statements may jeopardize the validity of the application or any patent issuing  
thereon.

Date 12/21/07

Nancy M. Lee  
Nancy M. Lee (signature)

# CURRICULUM VITAE

## NANCY M. LEE

## EDUCATION:

1963-67 Ph.D., Biochemistry  
University of Texas  
Austin, Texas

## PROFESSIONAL EXPERIENCE

1989-1995 Professor, Department of Pharmacology,  
University of Minnesota Medical School,  
Minneapolis, MN

1987-89 Professor, Department of Pharmacology and Langley Porter Psychiatric Institute, University of California, San Francisco, CA

1984-87 Adjunct Assoc. Professor, Dept. of Pharmacology  
and Langley Porter Psychiatric Institute, University  
of California, San Francisco, CA

1978-84 Associate Research Pharmacologist, Department of  
Pharmacology and Langley Porter Psychiatric  
Institute, University of California, San Francisco, CA

1972-1978 Assistant Research Biochemist Department of Pharmacology and Langley Porter Psychiatric Institute, University of California, San Francisco, CA

1968-1972 Postgradraduate Research Biochemist III-VI

Department of Pharmacology, University of California, San Francisco, CA

1967 Postdoctoral Fellow, Department of Biochemistry,  
Northwestern University, Evanston, Illinois

1963-1967 Research Assistant, University of Texas, Austin,  
Texas

## SOCIETY MEMBERSHIPS

Sigma Xi (1972)  
Society of Neuroscience (1974)  
American Society for Pharmacology and Experimental Therapeutics (1976)  
American Association for the Advancement of Science (1976)  
Western Pharmacology Society (1981)  
International Association of Women Bioscientist (1985)  
Society of Chinese Bioscientists in America (1985)

## AWARDS

American Heart Association Fellowship (1969 - 1972)  
USPHS Research Scientist Career Development Award (1976-1981)  
USPHS Research Scientist Award, K05 DA-00020: Beta-Endorphin Receptor and Dynorphin Receptor: Biochemical and Pharmacological Studies (1982-1994)  
California Alliance for Mentally Ill Award (1984)  
National Institute on Drug Abuse **MERIT** Award (1993 - 2003)

## COMMITTEE ACTIVITY

### National

Regular member for National Institute on Drug Abuse, Biomedical Research Committee (Washington, D.C.), 1980-83

Ad Hoc Committees for National Institutes of Health, National Science Foundation, Veterans Administration, and National Institute on Drug Abuse, 1980-present

Regular member for National Institute on Drug Abuse - Biomedical Research Committee, 1988-1993, Washington, D.C.

Chair for National Institute on Drug Abuse - Biomedical Research Committee, 1990 - 1993, Washington, D. C.

American Society for Pharmacology and Experimental Therapeutics - Regular Member, Committee on Drugs for Non-Medical Use, 1985-1989

Western Pharmacology Society, Secretary, 1985-1988

International Association of Women Bioscientists, Executive board member, 1985-present.

Regular member for National Institute of Mental Health - Neuropharmacology and Neurochemistry Committee, 1994-1998, Washington, D.C.

## RESEARCH SUPPORT

### Active Support

NIH R37-DA-02643 (**MERIT award**) Characterization and Regulation of Beta-Endorphin Receptor (1/81 - 7/03)

NIH P01-DA-08924, Opioid Peptide Analogs as Obstetric Analgesics (7/98-6/03)

NIH P01-DA11471, Non-opioid DynA: Molecular/Cellular/Physiological Studies (8/99-7/02)

### Pending Support

NIH R01 NS057231-01 – The Role of Zinc in sporadic ALS

## U.S. PATENTS

1. Therapeutic Uses of Dynorphin  
US Patent #4,361,553
2. Dynorphin Amide Analogs  
US Patent #4,462,941
3. Method for Controlling Blood Pressure  
US Patent #4,481,191
4. Clinical Usage of Dynorphin and Its Analogs  
US Patent #4,684,624
5. Method For Treating Cocaine Abuse  
US Patent Application # 08/476,691
6. Biomarker Panel for Colorectal Cancer  
US Patent Application
7. Drug Screening and Molecular Diagnostic Test for Early Detection of Colorectal Cancer, Reagents, Methods and Kits

## PUBLICATIONS

### Full Papers

1. Lee, N.M., Lansford, E.M., Jr. and Shive, William: A study of the mechanism lysine-sensitive aspartokinase control by lysine. *Biochem. Biophys. Res. Comm.* 24:315-318, 1966.
2. Lansford, E.M., Jr., Lee, N.M. and Shive, William: Regulation by lysine of production of threonine-sensitive aspartokinase. *Biochem. Biophys. Res. Comm.* 25:468-472, 1966.
3. Lansford, E.M., Jr., Lee, N.M. and Shive, William: A study of lysylribonucleic acid synthetase in relation to substrate conformation. *Arch. Biochem. Biophys.* 119:272-276, 1967.
4. Neuhaus, F.C. Carpenter, C.V., Miller, J., Lynch, J., Lee, N.M., Gregg, M. and Stickgold, R.A.: Enzymatic synthesis of D-ala-D-D-alanine. Control of D-Alanyl: D-Alanine ligase (ADP). *Biochem.* 8:5119-5124, 1969.
5. Kun, E., Kearney, E.B., Wiedemann, I. and Lee, N.M.: Regulation of mitochondrial metabolism by specific cellular substances: the nature of stimulation of mitochondrial glutamate metabolism by cytoplasmic component. *Biochem.* 8:4443-4449, 1969.
6. Kearney, E.B., Lee, N.M., Weidemann, I. and Kun, E.: The nature of inhibition of glutamate metabolism by incubation of liver mitochondria with ADP and 2,4-dinotrophenol and its prevention by a cytoplasmic factor. *J. Physiol. Chem. Physics* 1:575-583, 1969.
7. Skilleter, D.N., Lee, N.M. and Kun, E.: Malate dehydrogenases of ox kidney III. Comparison of the reactivity of sulfhydryl groups and their relationship to activities of the mitochondrial and cytoplasmic enzymes. *Europ. J. Biochem.* 12:533-539, 1970.
8. Kun, E., Kearney, E.B., Lee, N.M. and Wiedemann, I.: Interaction of a cytoplasmic factor with electron and ion transfer coupled functions of mitochondria. *Biochem. Biophys. Res. Comm.* 38:1002-1008, 1970.
9. Lee, N.M., Wiedemann, I., Johnson, K.L., Skilleter, D.N. and Kun, E.: The dependence of oxidative phosphorylation and ATPase of liver mitochondria on bound Mg<sup>++</sup>. *Biochem. Biophys. Res. Commun.* 40:1058-1062, 1970.

10. Lee, N.M., Wiedemann, I. and Kun, E.: Control of cation movements in liver mitochondria by a cytoplasmic factor. *Biochem. Biophys. Res. Comm.* 42:1030-1043, 1971
11. Lee, N.M., Wiedemann, I. and Kun, E.: Prevention of  $\text{Ca}^{++}$ - induced cation efflux from liver mitochondria by a cytoplasmic factor and by oligomycin. *FEBS Letters* 18:81-83, 1971.
12. Kun, E., Lee, N.M., Lin, D.C., Wiedemann, I., Johnson, K.L. and Dummel, R.J.: Extramitochondrial energy coupled processes by a cytoplasmic factor, in: *Molecular Basis of Electron Transport*, Proc. 4th Annual Biochem. PCRI Winter Symposia, Academic Press, N.Y., 1972.
13. Lee, N.M., Ho, I.K. and Loh, H.H.: Possible implications of gene expression in relation to morphine tolerance development. Proc. of the NAS-NRC Committee on Problems of Drug Dependence, Mexico City, p. 485, 1974.
14. Lee, N.M., Ho, I.K. and Loh, H.H.: The effect of chronic morphine treatment on brain chromatin template activities in animals. *Biochem. Pharmacol.* 24:1983-1987, 1975.
15. Lee, N.M. and Loh, H.H.: A study of deoxyribonucleic acid binding of narcotic analgesics. *Biochem. Pharmacol.* 24:1249-1251, 1975.
16. Oguri, K., Lee, N.M. and Loh, H.H.: Apparent protein kinase activity in oligodendroglial chromatin after chronic morphine treatment. *Biochem. Pharmacol.* 25:2371-2376, 1976.
17. Stokes, K.B. and Lee, N.M.: Morphine effects on RNA synthesis in purified oligodendroglial nuclei. *Proc. West. Pharmacol.* 19:48-54, 1976.
18. Lee, N.M. and Loh, H.H.: Alteration of RNA biosynthesis induced by chronic treatment of opiate. Intl. Narcotic Research Club Conference, Aberdeen, Scotland, July, 1976; *Opiates and Endogenous Opioid Peptides*, Elsevier, Amsterdam, pp. 423-426, 1976.
19. Loh, H.H., Lee, N.M. and Harris, R.A.: Alterations of macromolecule biosynthesis for chronic administration of opiates and ethanol, in *Alcohol Intoxication and Withdrawal: Experimental Studies, III, Advances in Experimental Medicine and Biology* (ed. Milton M. Gross) Plenum Press, New York, pp. 65-86, 1977.
20. Lee, N.M. and Loh, H.H.: Phosphorylation and methylation of chromatin proteins from mouse brain nuclei. *J. Neurochem.* 29: 547-550, 1977.
21. Stokes, K.B., Lee, N.M. and Loh, H.H.: Partial purification of DNA-dependent RNA polymerase from small dense nuclei of mouse brain. *Biochem. Pharmacol.* 27: 1787-1792, 1978.

22. Lee, N.M., Loh, H.H. and Li, C.H.: Morphine and endorphin on RNA synthesis in Advances in Biochemical Psychopharmacology (ed. E. Costa), Brescia, Italy, 1977, Raven Press, N.Y., 1978.
23. Loh, H.H., Lee, N.M. and Li, C.H.: B-Endorphin: stimulation of DNA dependent RNA formation, in Endorphins in Mental Health Research (ed. E. Usdin), Macmillan Press, London, 1978.
24. Lee, N.M., Craves, F. and Stokes, K.B.: Effect of opiates on macromolecule biosynthesis, in Neurochemical Mechanisms of Opiate Ligands (ed. H.H. Loh and D.H. Ross), Raven Press, N.Y., 1979.
25. Johnson, D.A., Lee, N.M., Cooke, R. and Loh, H.H.: Ethanol-induced fluidization of brain lipid bilayers: required presence of cholesterol in membranes for the expression of tolerance. Mol. Pharmacol. 15: 739-746, 1979.
26. Johnson, D.A., Lee, N.M., Cooke, R. and Loh, H.H.: Adaptation to ethanol-induced fluidization of brain lipid bilayers. Drug and Alcohol Dependence 4: 197-202, 1979.
27. Wu, Chuen-Shang C., Lee, N.M., Li, Choh Hao, Loh, H.H. and Yang, Jen Tsi: B-Endorphin: formation of  $\alpha$ -helix in lipid solutions. Proc. Natl. Acad. Sci. 76:3656-3659, 1979.
28. Johnson, D.A., Friedman, H.J., Cook, R. and Lee, N.M.: Adaptation to ethanol-induced fluidizability of brain bilayers: generalizable to other strains and species. Biochem. Pharmacol. 29:1673-1676, 1979.
29. Stokes, K. Bradley, Lee, N.M. and Loh, H.H.: Mouse brain DNA-dependent RNA polymerases after chronic morphine treatment. J. Neurochem. 34:1058-1064, 1980.
30. Johnson, D.A., Lee, N.M., Cooke, R. and Loh, H.H.: Adaptation to ethanol-induced fluidization of brain lipid bilayers: cross-tolerance and reversibility. Mol. Pharmacol. 17:52-55, 1980.
31. Hook, V.Y.H., Stokes, K.B. and Lee, N.M.: Evidence for biochemical adaptation in morphine tolerance dependence. Presented 1979; Life Sci., 1980; Endogenous and Exogenous Opiate Agonists and Antagonists (ed. Way, E. Leong), Pergamon Press, N.Y., pp. 493-496, 1980.
32. Hook, V.Y.H., Lee, N.M., and Loh, H.H.: Partial purification of nuclear protein kinase from small dense nuclei of mouse brain and the effect of chronic morphine treatment. J. Neurochem. 34:1274-1279, 1980.
33. Lee, N.M., Wu, C.C., Yang, J.T., Loh, H.H. and Li, C.H.: Circular dichroic study of  $\beta$ -endorphin conformation induced by membrane acidic lipids, in Neural Peptides and

Neuronal Communication, Advances in Biochemical Psychopharmacology, (ed. E. Costa and M. Trabucchi), Raven Press 22:285-290, 1980.

34. Lee, N.M., Friedman, H.J., Leybin, L., Cho, T.M., Loh, H.H. and Li, C.H.: Peptide inhibitor of morphine and  $\beta$ -endorphin-induced analgesia. Proc. Natl. Acad. Sci. USA 77:5525-5526, 1980.
35. Lee, N.M. and Smith, A.P.: A protein-lipid model of the opiate receptor. Life Sci. 26:1459-1464, 1980.
36. Lee, N.M., Friedman, H.J. and Loh, H.H.: Effect of acute and chronic ethanol treatment on rat brain phospholipid turnover. Biochem. Pharmacol. 29:2815-2818, 1980.
37. Lee, N.M., Leybin, L., Chang, J.K. and Loh, H.H.: Opiate and peptide interaction: effect of enkephalins on morphine analgesia. Europ. J. Pharmacol. 68: 181-185, 1980.
38. Wu, C-S., Lee, N.M., Ling, N., Chang, J.K., Loh, H.H. and Yang, J.T.: Conformation of  $\beta$ -endorphin analogs in cerebroside sulfate solution. Mol. Pharmacol. 19:302-306, 1981.
39. Friedman, H.J., Jen, M.F., Chang, J.K., Lee, N.M. and Loh, H.H.: Dynorphin: a possible modulatory peptide on morphine  $\beta$ -endorphin analgesia in mouse. Europ. J. Pharmacol. 69:357-360, 1981.
40. Hook, V.Y.H., Stokes, K.B., Lee, N.M. and Loh, H.H.: Possible nuclear protein kinase regulation of homologous RNA polymerases from small dense nuclei of mouse brain during morphine tolerance-dependence. Involvement of cyclic 3',5'-adenosine monophosphate. Biochem. Pharmacol. 30:2313-2318, 1981.
41. Tulunay, F.C., Jen, Ming-Feng, Chang, J.K., Loh, H.H. and Lee, N.M.: Possible regulatory role of dynorphin in morphine and  $\beta$ -endorphin induced analgesia. J. Pharmacol. Exptl. Therap. 219:296-298, 1981.
42. Huidobro-Toro, J.P., Yoshimura, K., Lee, N.M., Loh, H.H. and Way, E.L.: Dynorphin interaction on the  $\kappa$ -opiate site. Europ. J. Pharmacol. 72:265-266, 1981.
43. Morgan, R.L., Lee, N.M. and Loh, H.H.: The effect of ethanol tolerance on cholesterol organization and  $\text{Na}^+,\text{K}^+$ -ATPase activity in rat brain membrane proteins. Proc. West. Pharmacol. Soc. 41-44, 1981.
44. Tulunay, F.C., Jen, M-F., Chang, J-K., Loh, H.H. and Lee, N.M.: Possible regulatory role of dynorphin (1-13) on narcotic induced changes in naloxone efficacy. Europ. J. Pharmacol. 76:235-239, 1981.
45. Huidobro-Toro, J.P., Caturay, E., Lee, N.M., Loh, H.H. and Way, E.L.: Active sites in the  $\beta$ -endorphin structure for activation of the epsilon-opiate receptor. Intl. Narcotic Research

- Conference, Kyoto, Japan, 1981; Advances in Endogenous and Exogenous Opioids, pp. 374-376, 1981.
46. Lee, N.M., Huidobro-Toro, J.P., Smith, A.P. and Loh, H.H.:  $\beta$ -Endorphin receptor and its possible relationship to other opioid receptors, in Regulatory Peptides: Functional and Pharmacological Aspects, Advances in Biochemical Psychopharmacology (ed. E. Costa and M. Trabucchi), Raven Press, N.Y., pp. 75-89, 1982.
  47. Tulunay, F.C., Jen, M-F. and Lee, N.M.: Dynorphin: differential interactions with opiates and peptides in naive and morphine tolerant mice. Intl. Narcotic Research Conference, Kyoto, Japan, Advances in Endogenous and Exogenous Opioids, 1982.
  48. Aceto, M.D., Dewey, W.L., Chang, J.K. and Lee, N.M.: Dynorphin-1-13: effects in nontolerant and morphine-dependent rhesus monkeys. Europ. J. Pharmcol. 83:139-142, 1982.
  49. Huidobro-Toro, J. Pablo, Caturay, E.M., Ling, N., Lee, N.M., Loh, H.H. and Way, E.L.: Studies on the structural prerequisite for the activation of the  $\beta$ -endorphin receptor on the rat vas deferens. J.Pharmacol. Exptl. Therap. 222:262-269, 1982.
  50. Lee, N.M., Huidobro-Toro, J.P., Smith, A.P., Loh, H.H.,  $\beta$  -endorphin receptor and its possible relationship to other opioid receptors. In Regulatory Peptides: From Molecular Biology to Function (E. Costa and M. Trabucchi, eds.), New York: Raven Press, pp. 75-89. 1982.
  51. Yoshimura, K., Huidobro-Toro, J.P., Lee, N.M., Loh, H.H. and Way,E.L.: Activation of  $\kappa$ -opiate sites by dynorphin in the myenteric plexus. In Regulatory Peptides: From Molecular Biology to Function (E. Costa and M. Trabucchi, eds.), New York, Raven Press, pp. 91-98, 1982.
  52. Yoshimura, K., Huidobro-Toro, J.P., Lee, N.M., Loh, H.H. and Way,E. L.: Kappa opioid properties of dynorphin and its peptide fragments on the guinea pig ileum. J. Pharmacol. Exptl. Therap. 222:71-79, 1982.
  53. Sanchez-Blazquez, P., Garzon, J. and Lee, N.M.: Different modes of opiate interaction in rat vas deferens. Intl. Narcotic Res. Conf., N. Falmouth, Massachusetts, 1982; Life Sci. 31:1683-1686, 1982.
  54. Garzon, J., Jen, M.F., Sanchez-Blazquez, P. and Lee, N.M.: Dynorphin(1-13): a long-lasting inhibitor of opiate receptor binding in vitro. Intl. Narcotic Research Conference, N. Falmouth, Massachusetts, 1982; Life Sci. 31:1789-1792, 1982.
  55. Jen, M.F., Garzon, J. and Lee, N.M.: Decreased dihydromorphine and D-ala<sup>5</sup>-D-Leu<sup>2</sup>-enkephalin binding in vitro after dynorphin pretreatment in mice in vivo. Intl. Narcotic Res. Conf., N. Falmouth, Massachusetts, 1982; Life Sci. 31:1813-1816, 1982.

- 56 Zhu, Y.C., Huidobro-Toro, J.P., Lee, N.M., Loh, H.H. and Way, E.L.: Interaction of dynorphin with neurotensin on the guinea pig ileum myenteric plexis. *Intl. Narcotic Res. Conf.*, N. Falmouth, Massachusetts, 1982; *Life Sci.* 31:1825-1828, 1982.
57. Lee, N.M. and Becker, C.: Alcohol in Medical Pharmacology (ed. B.G. Katzung), Lange Press, 1982.
58. Garzon, J., Jen, M.F., Tulunay, F.C. and Lee, N.M.: Differential modification of opiate receptor activity by arylsulfatase treatment. *Biochemical Pharmacol.* 32:1523-1528, 1983.
59. Smith, A.P., Lee, N.M. and Loh, H.H.: The multiple site  $\beta$ -endorphin receptor. *Trends Pharmacol. Sci.* 4:163-164, 1983.
60. Sanchez-Blazquez, P., Garzon, J. and Lee, N.M.: Functional opiate receptor in mouse vas deferens: evidence for a complex interaction. *J. Pharmacol. Exptl. Therap.* 226:706-711, 1983.
61. Jen, M.F., Garzon, J., Loh, H.H. and Lee, N.M.: Dynorphin-(1-13): the effect of in vivo treatment on opiate bindings in vitro. *Europ. J. Pharmacol.* 91:95-99, 1983.
62. Woo, S.K., Tulunay, F.C., Loh, H.H. and Lee, N.M.: Effect of dynorphin-1-13 and related peptides on respiratory rate and morphine-induced respiratory rate depression. *Europ. J. Pharmacol.* 96: 117-122, 1983.
63. Morgan, R.L., Lee, N.M. and Loh, H.H.: In vivo incorporation of a cholesterol-like fluorescent probe into rat brain membranes. *J. Pharmacol. Methods* 10:19-30, 1983.
64. Sanchez-Blazquez, P., Garzon, J. and Lee, N.M.: Opioid peptides derived from pre-proenkephalin B sequence: biological evaluation in guinea pig ileum and mouse vas deferens. *Proc. West. Pharmacol. Soc.* 26:85-88, 1983.
65. Garzon, J., Sanchez-Blazquez, P. and Lee, N.M.: Dynorphin inhibition of opiate binding: specificity and reversibility in vitro. *Proc. West. Pharmacol. Soc.* 26:299-303, 1983.
66. Lee, N.M.: Is dynorphin a k-ligand? *Proc. West. Pharmacol. Soc.* 26:309-311, 1983.
67. Garzon, J., Sanchez-Blazquez, P. and Lee, N.M.: Effect of human  $\beta$ -endorphin on the binding of different opiates to mouse brain membranes. *Life Sci.* 33(SI): 279-282, 1983.
68. Garzon, J., Sanchez-Blazquez, P., Hollt, V., Lee, N.M. and Loh, H.H.: Endogenous opioid peptides: comparative evaluation of their receptor affinities in the mouse brain. *Life Sci.* 33(SI):291-294, 1983.

69. Loh, H.H., Smith, A.P. and Lee, N.M.: Dynorphin: pharmacology and clinical implications. Proc. Intl. Congress Clin. Pharmacol., 1983.
70. Lee, N.M.: The role of dynorphin in narcotic tolerance mechanisms, in NIDA Monograph, Mechanisms of Tolerance/Dependence 54:162-167, 1984.
71. Lee, N.M. and Smith, A.P.: Possible regulatory function of dynorphin and its clinical implications. Trends Pharmacol. Sci. 55:108-110, 1984.
72. Sanchez-Blazquez, P., Garzon, J. and Lee, N.M.: Leu<sup>5</sup>-enkephalin containing peptides derived from a common precursor: evaluation of opioid activity in in vitro bioassays. Europ. J. Pharmacol. 98:389-396, 1984.
73. Huidobro-Toro, J-P., Zhu, Y-X., Lee, N.M., Loh, H.H. and Way, E.L.: Dynorphin inhibition of the neuropeptides contractile activity on the myenteric plexus. J. Pharmacol. Exptl. Therap. 228:293-303, 1984.
74. Garzon, J., Sanchez-Blazquez, P., Gerhart, J., Loh, H.H. and Lee, N.M.: Dynorphin 1-13: interaction with other opiate ligand bindings in vitro. Brain Res. 302:392-396, 1984.
75. Sanchez-Blazquez, P., Garzon, J., Lee, N.M. and Hollt, V.: Opiate activity of peptides derived from the three opioid peptide families on the rat vas deferens. Neuropeptides 5:181-184, 1984.
76. Baskin, D.S., Hosobuchi, Y., Loh, H.H. and Lee, N.M.: Dynorphin-(1-13) improves survival in cats with focal cerebral ischemia. Nature 312: 551-552, 1984.
77. Garzon, J., Sanchez-Blazquez, P., Gerhart, J., Loh, H.H. and Lee, N.M.: Dynorphin A: inhibitory effect on other opiate ligand bindings in the mouse brain. Biochem. Pharmacol. 33:2609-2614, 1984.
78. Garzon, J., Sanchez-Blazquez, P. and Lee, N.M.: <sup>3</sup>H-Ethylketocyclazocine binding to mouse brain membranes: Evidence for a kappa opioid receptor type. J. Pharmacol. Exptl. Therap. 231:33-37, 1984.
79. Sanchez-Blazquez, P., Chang, J.K., Garzon, J. and Lee, N.M.: B-29: chemical synthesis and pharmacological properties in opioid systems in vitro. Neuropeptides 4:369-374, 1984.
80. Smith, A.P. and Lee, N.M.: Search for an endogenous DFPase in mouse brain. Proc. West. Pharmacol. Soc. 27:569-571, 1984.
81. Rezvani, A., Muller, J., Kadambi, S.R., Chang, J.K., Lee, N.M. and Way, E.L.: Opioid-like properties of seven dynorphin(1-10) analogs. Neuropeptides 5:153-156, 1984.

- 82 Baskin, D.S., Kuroda, H., Hosobuchi, Y. and Lee, N.M.: Treatment of stroke with opiate antagonists - effects of exogenous antagonists and dynorphin 1-13. *Neuropeptides* 5:307-310, 1984.
83. Landhal, H.S., Garzon, J. and Lee, N.M.: Mathematical modeling of opiate binding to mouse brain membrane. *Bull. in Math. Biol.* 47:503-512, 1985.
84. Farahbakhah, Z.T., Deamer, D.W., Lee, N.M. and Loh, H.H.: Enzymatic reconstitution of brain membrane and membrane opiate receptors. *J. Neurochem.* 46:953-962, 1986.
85. Wu, C-S. C., Lee, N. M., Loh H. H. and Yang J. T.: Competitive binding of dynorphin-(1-13) and  $\beta$ -endorphin to cerebroside sulfate in solution. *J. Biol. Chem.* 261:3687-3691, 1986.
86. Kuroda, H., Baskin, D. S., Matsui, T., Loh, H. H., Hosobuchi, Y. and Lee, N. M.: Effects of dynorphin-(1-13) on opiate binding and dopamine and GABA uptake in stroked cat brain. *Brain Res.* 379:68-74, 1986.
87. Lee. N. M. and Landahl, H. D.: Dynorphin: Specific binding to opiate receptors. *NIDA Monograph* 71:19-27, 1986.
88. Feng, F., Fields, H. and Lee, N. M.: Action at the mu receptor is sufficient to explain the supraspinal analgesic effect of opiates. *J. Pharmacol. Exptl. Therap.* 238:1039-1044, 1986.
89. Gilbeau, P.M., Hosobuchi, Y. and Lee, N. M.: Dynorphin effects on plasma concentrations of anterior pituitary hormones in the nonhuman primate. *J. Pharmacol. Exptl. Therap.* 238: 974-977, 1986.
90. Loh, H.H., Smith, A.P. and Lee, N.M.: The role of dynorphin in opiate analgesia and tolerance , in Central Actions of ACTH and Related Peptides (eds. D. de Wied and W. Ferrari), FIDIA Research Series, Symposia in Neuroscience, vol. 4, pp. 199-206, Liviana Press, Padova, 1986.
91. Roy, S, Lee, N. M. and Loh, H. H.: Mu-opioid receptor is associated with phosphatase activity. *Biochem. Biophys. Res. Comm.* 140:660-665, 1986.
92. Lee, N.M. and Smith, A. P.: Ethanol, in Toxicology of CNS Depressants (ed. I. K. Ho), pp. 109-120, CRC press, Inc., Boca Raton, Fl, 1987.
- 93 Gilbeau, P. M., Hosobuchi, Y. and Lee, N. M.: Consequence of dynorphin-A administration on anterior pituitary hormone concentrations in the adult male rhesus monkey. *Neuroendocrinology* 45:284-289, 1987.
94. Hasegawa, J, Loh, H. H. and Lee N. M.: Lipid requirement for mu opioid receptor bindings. *J. Neurochemistry* 49:1007-1012, 1987.

- 95 Abood, M. E., Lee, N. M. and Loh, H. : Modification of opioid agonist binding by pertussis toxin. *Brain Research* 417:70-74, 1987.
- 96 Green, P. and Lee, N. M.: Dynorphin A-(1-13) attenuates withdrawal in morphine-dependent rats: effect of route of administration. *Europ. J. Pharmacol.* 145:267-272, 1988.
97. Smith, A. P. and Lee, N. M.: Pharmacology of Dynorphin. *Ann. Rev. Pharmacol. Toxicol.* 28:123-140, 1988.
98. Roy, S., Zhu, Y-X, Lee, N. M. and Loh, H. H.: Different molecular weight forms of opioid receptors revealed by polyclonal antibodies. *Biochem. Biophys. Res. Comm.* 150:237-244, 1988.
99. Roy, S., Zhu, Y.X., Loh, H.H. and Lee, N.M.: A Monoclonal antibody that inhibits opioid binding to rat brain membranes. *Biochem. Biophys. Res. Comm.* 154:688-693, 1988.
100. Bero, L. A., Roy S. and Lee N. M.: Identification of endogenous opioid receptor components in rat brain using a monoclonal antibody. *Mol. Pharmacol.* 34:614-620, 1988.
101. Lee, N.M., Smith, A.P. and Loh, H.H.: Opioid receptors and their second messenger systems. In *Biowarning System in the Brain* (Eds. H. Takagi, Y. Oomura, M. Ito, M. Otsuka), pp. 179-188, University of Tokyo Press, 1988.
102. Fedynyshyn, J. P., Kwiat, G, and Lee, N. M.: Characterization of high affinity opioid binding sites in rat periaqueductal gray P2 membrane. *Eur. J. Pharmacol.* 159:83-88, 1989.
103. Fedynyshyn, J. and Lee, N.M.: Mu type opioid receptors in rat periaqueductal gray-enriched P2 membrane are coupled to guanine nucleotide binding proteins. *Brain Research* 476:102-109, 1989.
104. Schofield, P.R., McFarland, K.C., Hayflick, J.S., Wilcox, J.N., Cho, T.M., Roy, S., Lee, N.M., Loh, H.H. and Seeburg, P.H.: Molecular characterization of a new immunoglobulin superfamily protein with potential roles in opioid binding and cell contact. *EMBO Journal* 8:489-495, 1989.
105. Roy, S., Loh, H.H., Zhu, Y.X., Smith, A.P., Green, P.G., Bero, L., and Lee, N.M.: Preparation and characterization of monoclonal antibodies to purified opioid receptor. Chapter in "Neurochemical Pharmacology 1988 - A Tribute to B.B. Brodie," Symposium by Fidia Research Foundation, Raven Press, pp. 177-188, 1989.
106. Landahl, H. D., Garzon, J. and Lee, N. M.: Computer nalysis of the effect of beta-endorphin and dynorphin and related compounds on opiate binding to mouse brain membrane. *Comput. Biol. Med.* 19(3):151-162, 1989.

107. Fedynyshyn, J. P. and Lee, N. M. : Mu type opioid receptors in rat periaqueductal gray-enriched P2 membrane are coupled to G-protein-mediated inhibition of adenylyl cyclase. FEBS Letters 253:23-27, 1989.
108. Wu, C-S. C., Hasegawa, J., Smith, A. P., Loh, H. H., Lee, N. M., and Yang, J. T.: Opioid-binding protein (OBCAM) is rich in  $\beta$ -sheets. J. Protein Chem. 9:3-7, 1990.
109. Roy, S., Ramakrishnan, S., Loh, H.H. and Lee, N.M.: Chronic morphine treatment selectively suppresses macrophage colony formation in bone marrow. Europ. J. Pharmacol. 193:359-363, 1991.
110. Smith, A.P., Loh, H.H. and Lee, N.M.: New approaches to understanding of opioid receptor function. Proceeding in a Taiwan Symposium, 1991.
111. Roy, S., Ge, B. L., Ramakrishnan, S., Lee, N. M. and Loh, H. H.: [ $^3$ H]-Morphine binding is enhanced by IL-1-stimulated thymocyte proliferation. FEBS Letters 287:93-96, 1991.
112. Roy, S., Loh, H. H., and Lee, N. M.: Dynorphin blocks opioid inhibition of macrophage-colony stimulating factor-induced proliferation of bone marrow cells. Europ. J. Pharmacol. 202:355-359, 1991.
113. Smith, A. P., Loh, H. H. and Lee, N. M.: Cellular mechanisms of opioid tolerance/dependence. In Rassenga Clinico Scientifica, 1992.
114. Lane, Cynthia M., Elde, R.P., Loh, H.H., Lee, N.M.: Regulation of an opioid-binding protein in NG108-15 cells parallels regulation of  $\delta$ -opioid receptors, Proc. Natl. Acad. Sci. (USA) 89:11234-11238, 1992.
115. Ann, D. K., Hasegawa, J., Ko, J.-L., Chen, S. T., Lee, N. M. and Loh, H. H.: Specific reduction of d-opioid receptor binding in transfected NG108-15 cells. J. Biol. Chem. 267:7921-7926, 1992.
116. Roy, S., Ge, B. L., Loh, H. H. and Lee, N. M.: Characterization of  $^3$ H-morphine binding to interleukin-1-activated thymocytes. J. Pharmacol. Exptl. Therap. 263:451-456, 1992.
117. Ko, J. L., Lee, N. M. and Loh, H. H.: Characterization of  $I^{125}$ -beta-endorphin cross-linked proteins in NG108-15 cell membranes: A 25 kilo dalton protein with properties of delta-opioid binding site. J. Biol. Chem. 267:12722-12727, 1992.
118. Lippman, D. A., Lee, N. M. and Loh, H. H.: Opioid-binding cell adhesion molecule (OBCAM)-related clones from a rat brain cDNA library. Gene 117:249-254, 1992.
119. Jin, W., Lee, N. M., Loh, H. H. and Thayer, S. A.: Dual-excitatory and inhibitory effects of opioids on intracellular calcium in neuroblastoma x glioma hybrid NG108-15 cells. Mol. Pharmacol. 42:1083-1089, 1992.

120. Arany, I., Zhang, X., Loh, H. H. and Lee, N. M.: Antisense proenkephalin cDNA transfection decreases opioid binding in NG108-15 cells. Mol. Brain Res., 16, 295-302, 1992.
121. Takemori, A. E., Loh, H. H. and Lee, N. M.: Suppression by dynorphin A-(1-13) of the expression of opiate withdrawal and tolerance in mice. Europ. J. Pharmacol.: 221:223-226, 1992.
122. Smith, A. P., Loh, H. H. and Lee, N. M.: Characterization of opioid binding proteins and other molecules related to opioid function, in: *Handbook of Experimental Pharmacology: OPIOIDS I*, Ed. by Herz, A., Springer-Verlag, Berlin, Vol. 104/I, pp. 37-52, 1993.
123. Loh, Horace H., Smith, Andrew P. and Lee, Nancy M.: Effects of Opioids on Proliferation of Mature and Immature Immune Cells, in *Drugs of Abuse, Immunity, and AIDS*, ed. by Friedman, H., Specter, S. and Klein, T. W., Plenum Publishing Corp., New York, pp.29-33, 1993.
124. Jin, W., Lee, N. M., Loh, H. H. and Thayer, S. A.: Opioid-induced of voltage-gated channels parallels expression of w-conotoxin-sensitive channel subtype during differentiation of NG108-15 cells. Mol. Brain Res., 607, 17-22, 1993.
125. Takemori, A. E., Loh, H. H. and Lee, N. M.: Suppression by Dynorphin A and [Des-tyr1]Dynorphin A peptides of the expression of opiate withdrawal and tolerance in morphine-dependent mice. J. Pharmacol. Exptl. Therap., 266:121-124, 1993.
126. Chakraborti, A., Lippman, D. A. Loh, H. H., Kozak, C. A., and Lee, N. M.: Genetic mapping of opioid binding protein gene(s) to mouse chromosome 9. Mammalian Genome, 4:179-182, 1993.
127. Gavitrapong, P., Zhang, X., Loh, H. H. and Lee, N. M.: Transfection of NG108-15 cells with antisense OBCAM cDNA alters opioid receptor-G-protein interaction J.Biol.Chem, 286:18280-18285, 1993
128. Jin, W., Lee, N. M., Loh, H. H and Thayer, S. A.,: Opioids mobilize calcium from inositol 1,4,5-Trisphosphate-sensitive stores in NG108-15 cells. J. of Neuroscience, 14(4): 1920-1929, 1994.
129. Wick, M. J, Ann, D. K, Lee, N. M. and Loh, H. H.: Substractive cloning of a cDNA encoding a novel zinc finger protein regulated by chronic opioid agonist treatment of NG108-15 cells. Gene, 152: 227-232, 1995.
130. Lee, N. M.: DynorphinA - a rectifying peptide. NIDA monograph. 147, Discovery of Novel Opioid Medications, p. 161-169, 1995.

131. Kalyuzhny, A., Lee, N. M. and Elde, R.: An opioid binding protein (OBCAM) is specifically downregulated by chronic morphine treatment in dorsal root and trigeminal ganglia. *Neuroscience*, 66(4), 943-949, 1995.
132. Pentel, P.R., Wanankul, W., Hooke, L.P. Jones, C.R.N., Hatsukami, D., Anderson, W. R., and Lee, N. M.: Effects of high intravenous doses of dynorphinA(1-13) on tail flick latency and central nervous system histology in rats. *Pharmacology Biochemistry and Behavior*, 51, 387-390, 1995.
133. Shark, K. B. and Lee, N. M.: Cloning, sequencing, and localization to chromosome 11 of a cDNA encoding a human opioid-binding cell adhesion molecule (OBCAM). *Gene*, 155, 213-217, 1995.
134. Lane, C. M., Jones, C. R., Reisine, T., Yu, L and Lee, N. M.: Alteration of OBCAM conformation as a result of opioid receptor expression and opioid ligand treatment. *Brain Research*, 698, 15-22, 1995.
135. Hooke, L. P., He, L., and Lee, N. M.: Dynorphin A modulates acute and chronic opioid effects. *J. Pharmacol. Exptl. Therap.*, 273, 292-297, 1995.
136. Hooke, L. P., He, L., and Lee, N. M.: [Des-Tyr<sup>1</sup>] Dynorphin A(2-17) has naloxone-insensitive antinociceptive effect in the writhing assay. *J. Pharmacol. Exptl. Therap.*, 273, 802-807, 1995.
137. He, L and Lee, N.M.: DynorphinA-(2-17) Restores spinal/Supraspinal Morphine Synergy in Morphine Tolerant Mice. *J. Pharmacol. Exptl. Therap.*, 280, 1210-1214, 1997.
138. Konstantin N. Yarygin, X-H Zhang and Lee, N. M.: Non-Opioid Dynorphin Binding Site on Secretory Vesicles of a Pituitary-derived Cell Line. *Brain Research*, 79, 99-107, 1998
139. He, L and Lee, N.M.: *Delta* Opioid Receptor Enhancement of *Mu* Opioid Receptor-Induced Antinociception in Spinal Cord, *J. Pharmacol. Exptl. Therap.*, 285, 1181-1186, 1998
140. Riba, P, Ben, Y, Smith, A. P. Furst, S and Lee N. M. Morphine Tolerance In the Spinal Cord is due to the Interaction between  $\mu$  and  $\delta$  Opioid Receptors. *J. Pharmacol. Exptl. Therap.*, 300:265-272, 2001.
141. Gant, T. M. Riba, P. and Lee. N. M. Morphine Tolerance in Independent of Polymorphisms in Opioid Receptor Sequences, *Brain Research Bulletin*, 55 (1): 59-63, 2001.
142. Riba, P, Nguyen, T. M-D, Furst, S, Schiller, P.W. and Lee N. M.: [Dmt<sup>1</sup>]DALDA: A potent systemically-active analgesic peptide acting at  $\mu$  opioid receptors, *Current Medicinal Chemistry*, 9, 31-39, 2002.

143. Lee, N. M. and Smith, A. P.: Opioid Receptor Polymorphisms and Opioid Abuse. *Pharmacogenomics*, 3 (2), 219-227, 2002.
144. Ben, Y., Schiller, Peter W. and Lee, N. M. Tolerance Develops in Spinal Cord, But not in Brain with Chronic [Dmt<sup>1</sup>]DALDA Treatment. Submitted, *J. Pharmacol. Exptl. Therap.*, 2003.
145. Smith, A. P. and Lee, N. M. Opioid Receptor Interactions: Local and Nonlocal, Symmetric and Nonsymmetric, Physical and Functional. *Life Science*, 73, 1873-1893, 2003.
146. Fong, S, Itahana, Y, Sumida, T. Singh, J, Coope, JP, Liu, Y, Richards, PC, Bennington, JL, Lee, NM, Debs, RJ and Desprez PY. Id-1 as a Molecular Target in Therapy for Breast Cancer Cell Invasion and Metastasis. *Proc Natl Acad Sci USA*, 100(23); 13543-8, 2003.
147. Chen, Ling-Chun, Hao, Chunyi, Chiu, Yanek S. Y., Wong, Patrick, Melnick, Jane S., Brotman, Martin, Moretto, John, Mendes, Fredrick, Smith, Andrew P., Bennington, James L. and Lee, Nancy M. Alteration of Gene Expression in Normal-Appearing colon Mucosa of APC<sup>min</sup> Mice and Human Cancer Patients. *Cancer Research*, 64, 3694-3700, 2004.
148. Smith, Andrew P. and Lee, Nancy M. Role of Heteromeric GPCR Interactions in Pain/Analgesia. p.349-362, In *G-Protein Coupled receptors: Signaling, Dimerization, and Neuropharmacology*, in *Contemporary Clinical Neuroscience*, series editors Ralph Lydic and Helen Baghdoyan, Humana Press, U.S.A., 2005.
149. Chen, L-C, Smith A.P. Ben, Y, Zukic B, Ignacio S, Moore, D, and Lee, N. M. Temporal Gene Expressopm Patterns in mutant SOD1 mouse. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 11: 1-8, 2004.
150. Hao, Chunyi, Moore, Dan H., Wong, Patrick, Bennington, James L., Lee, Nancy M. and Chen, Ling-Chun, Alteration of Gene Expression in Macroscopically Normal Colonic Mucosa from Individuals with a Family History of Sporadic Colon Cancer, *Clinical Cancer Research*, 11, 1400-1407, 2005.
151. Hao, Chun-Yi, Dan H. Moore, Chiu, Yanek S. Y., Wong, Patrick, Bennington, James L., Smith, Andrew P., Chen, Ling-Chun and Lee, Nancy M., Altered Gene Expression In Normal Colonic Mucosa Of Individuals With Polyps Of The Colon, *Diseases of the Colon and Rectum*, 48, 2329-2335, 2005.
152. Ben, Yong, Smith, Andrew P., Schiller, Peter W., and Lee, Nancy M., Tolerance Develops In Spinal Cord, But Not In Brain With Chronic [Dmt1]DALDA Treatment, *Brit. J. Pharmacology*, 143: 987-993, 2004.
153. Smith , Andrew P. and Lee, Nancy M., Role of Heteromeric GPCR Interactions in Pain/Analgesia. In *Contemporary Clinical Neuroscience: The G Protein-Coupled*

- Receptors Handbook, Ed. By L. A. Devi, p. 349-362, Humana Press Inc., Totowa, NJ, 2005.
154. Ignacio, Sheila, Moore, Dan H., Smith, Andrew P and Lee , Nancy M., Effect of Neuroprotective Drugs on Gene Expression in G93A/SOD1 Mice. Ann. N. Y. Acad of Sci., 1053, 121-136, 2005.
- 155 . Smith, Andrew P. and Lee, Nancy M., Role of Zinc in ALS, Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 8: 131-143, 2007.
156. Lu, Shan, Chiu,Yanek S.Y, Smith,Andrew P., Moore, Dan, and Lee, Nancy M. Gene Expression Analysis Of Non-Surgically Removed Colon Tissue Correlates With Risk Of Colon Cancer, Submitted, 2007

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals  
Books

Search PubMed for

[Go] [Clear]

Limits Preview/Index History Clipboard Details

Display AbstractPlus Show 20 Sort By Send to

[All: 1] Review: 0

1: Am J Epidemiol. 1995 May 1;141(9):863-71.

FULL FINAL TEXT  
OXFORD JOURNALS

Links

### How accurate is self-reported family history of colorectal cancer?

**Aitken J, Bain C, Ward M, Siskind V, MacLennan R.**

University of Queensland Medical School, Department of Social and Preventive Medicine, Brisbane, Australia.

Much of the evidence that supports a relation between a positive family history of and increased risk for colorectal cancer is based on information obtained exclusively from patients. There have been few assessments of the accuracy of such data. The validity of self-reported family history of colorectal cancer was assessed in the course of a case-control study of colorectal adenomas conducted among patients aged 20-75 years who underwent colonoscopy in Brisbane, Australia between 1980 and 1985. Family histories reported by a subsample of 237 colonoscopy patients (74 cases and 163 controls) were compared with relatives' medical records and death certificates. Patients' reports of colorectal cancer in 90 relatives were confirmed for 70 (77.8%; 95% confidence interval (CI) 67.8-85.9). Among 124 reports by patients of relatives who had other abdominal cancer or bowel conditions, 114 (91.9%; 95% CI 85.7-96.1) were confirmed to be correct, while 10 (8.1%) were found to be colorectal cancer. Finally, 105 (99.1%; 95% CI 94.9-100.0) of a random sample of 106 completely negative reports by patients were confirmed to be correct. Overall, 77% of positive family histories (any positive relatives) were confirmed, and it was estimated that 98% of negative family histories (no positive relatives) were correct. Cases were slightly more accurate than controls in reporting both positive and negative histories among their relatives. By extrapolation of these results to the total sample of 1,244 patients in the larger case-control study, sensitivity of self-reported positive family history was estimated to be 0.87 among cases and 0.82 among controls, and specificity was estimated to be 0.97 in both groups.

PMID: 7717363 [PubMed - indexed for MEDLINE]

### Related Links

Validity of self-reported endoscopies of the large bowel and implications for estimates of colorectal cancer [Am J Epidemiol. 2007]

Accuracy of reporting of family history of colorectal cancer. [Gut. 2004]

Validation of family history data in cancer family registries [Am J Prev Med. 2003]

Family history of colorectal adenomatous polyps and increased risk for colorectal cancer [Am J Gastroenterol. 1998]

An analytical method for assessing patterns of familial aggregation in case-control studies [Am J Epidemiol. 1992]

See all Related Articles...

Display AbstractPlus Show 20 Sort By Send to

[Write to the Help Desk](#)